Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

COVID-19 vaccination in pregnancy: A review of maternal and infant benefits

Emmanuel Lamptey,a,c,* Ephraim Kumi Senkyireb, Moses Tia Banoyac, Stanley Yaidood
d

a Institute of Life and Earth Sciences (Including Health and Agriculture), Pan African University, University of Ibadan, Nigeria
b Ga-West Municipal Hospital Ghana Health Service, Ghana
c Methodist University, Ghana
d St. Gregory Catholic Hospital Kasoa, Ghana

ARTICLE INFO

Keywords:
COVID-19 vaccines
Antenatal immunization
Infants
Pregnant

ABSTRACT

Pregnant women with COVID-19 are more likely to be admitted to the intensive care unit and their babies born prematurely. Clinical trials excluded pregnant women from the vaccine and safety data were limited. However, an increasing number of studies have demonstrated the safety and immunogenicity of the COVID-19 vaccines for pregnant women and their babies including evidence of maternal transfer of antibodies. In addition to these benefits, the vaccines are proved to be effective for both the pregnant women and infants. The current evidence supports the safety, immunogenicity of the COVID-19 vaccine and its effectiveness in reducing the theoretical risk of the infection among pregnant women and their infants. This review summarizes the recent data on the beneficial effects of COVID-19 immunization on both the pregnant mother and infant.

1. Introduction

Pregnant women are more susceptible to COVID-19 infection and severe illness due to physiological and immunological changes.1,2 The infection spreads quickly through the maternal vasculature, and the symptoms manifest after an incubation period of one day to 14 days with a mean of 4.5–5.8 days.3,4 Inflammatory cytokines (IL-1, IL-2, IL-7, IL-10, granulocyte-colony stimulating factor, interferon-alfa-inducible protein 10) and tumour necrosis alfa are seen to increase in the blood, placental and vagina samples of pregnant women following COVID-19.5,6 The high levels of these mediators, together with fall in T cells and rising leukocytes and neutrophils-lymphocyte ratio have been associated with the severity of the infection and its related complications.1,7,8

Seroprevalence studies suggest that women in both the first, second and third trimester of pregnancy have an equal risk of contracting the virus, but severe complications are higher in the third trimester.9,10 There are high rates of admission to ICU for women who test positive for the infection with the potential to develop pre-eclampsia and the need for an emergency caesarean at the time of birth.11 Women of black, Asian and minority descent and those aged 35 years with a BMI of 25 or more having the underlying condition of hypertension and diabetes are more vulnerable to these complications.12 A study done on September 25, 2020, by the U.S Centre for Disease Control and Prevention among 598 pregnant women with confirmed cases reported more hospitalization and ICU admission of expectant mothers than non-pregnant women.13 The present review evaluates the extent of immunogenicity, safety and clinical outcomes of the vaccine to the mother and their babies. This paper summarizes relevant studies and data assessing these benefits of the COVID-19 vaccine in pregnant women and their newborns.

1.1. Effect of COVID-19 on pregnancy

Pregnant women across the globe have faced many uncertainties since the arrival of the SARS-COV-2.1 For instance, the hypercoagulability of pregnancy makes women susceptible to blood clot formation. Patients with COVID-19 show increased risk of clotting suggesting...
pregnant women have more potential risk of maternal venous thrombosis. This may be worsened by reduced mobility due to hospital admission. The implications do not only affect the pregnant mother but also the fetus and the neonate as well.

There is emerging evidence that vertical transmission is possible but occur in minimal cases of infected pregnant women. In one retrospective cross-sectional study of 45 newborns from mothers with COVID-19, 3 (6.6%) tested positive by throat swab. In a related event, out of 836 babies born to infected women, 35 of them (4.2%) were confirmed positive by a polymerase chain reaction, and they showed no respiratory complications. Walker et al. reported that 8/292 newborns from infected expectant women tested positive on vaginal delivery while 20/375 were caesarean section. IgM antibodies for SARS-COV-2 are identified in neonatal serum at birth. These reports imply neonatal immune response to the virus in-utero because it is well known that IgM antibodies do not cross the placenta. Neonates born to COVID-19 mothers, although showed no SARS-COV-2 infection, exhibit perinatal complications with placental tissues confirmed positive for the virus. A review done by Yang et al. reported the following adverse fetal and neonatal outcomes: preterm birth (21.3%); stillbirth (1.2%); fetal distress (10.7%); neonatal deaths (1.2%), and neonatal asphyxia (1.2%).

In a study by Chan et al. spontaneous and induced abortion was reported among 6% of pregnant women with the COVID-19 infection. Studies have contrasting views. It is established that high fevers in pregnant women result in thrombocytopenia and venous thrombotic events. These events, which range from deep vein thrombosis to pulmonary embolism, splanchic, portal or hepatic vein thrombosis, CVST, and ocular vein thrombosis, befell 5–21 days after COVID-19 vaccine delivery in unanticipated places such as the abdomen and brain. However, in a study in the USA of 46 079 pregnancies revealed that immunization against covid-19 was safe and did not increase the risk of preterm birth or small for gestational age babies. This was in consonance with observational studies from the USA, Norway and Israel which found no risks related to mRNA COVID-19 vaccines administered during pregnancy. Again, population-based observational retrospective studies from Sweden, Norway and Canada assessing results in more than 250 000 pregnancies provided strong evidence concerning safety of COVID-19 vaccination in pregnancy. These studies found no associated increased risks for postpartum hemorrhage, choioamnionitis, cesarean delivery, neonatal care, or low Apgar score. All these findings are extremely in consistent with previous evidence globally. Despite previous validated trials, there are ongoing trials pending data safety. A prospective observational study is being conducted by Janssen which aim to quantify obstetric, neonatal, and infant outcomes. Objectively, Janssen will oversee a phase 2 placebo-controlled trial in more than 800 pregnant women. Considering the paucity of data, the known risk of coronavirus disease during pregnancy is likely to outweigh the not yet fully elucidated risk of SARS-CoV-2 vaccines reassuring safety and efficacy. To assess the safety, tolerability, and immunogenicity of the SARS-CoV-2 vaccination in pregnant women aged 18 and older, Pfizer will start its randomized placebo-controlled observer blind global second phase trial including 4000 vaccinated pregnant women between 24 and 34 weeks. To determine whether to receive the vaccine or the placebo, each woman will take part in the study for 7–10 months, and their neonates will be observed till they are 6 months old.

1.3. Benefits of COVID-19 vaccination during pregnancy for pregnant women

Studies have evaluated the immunogenicity, safety and tolerability of some of the COVID-19 vaccines in pregnant women. More reliable and reassuring information derived from the Vaccine Adverse Event Reporting system justifies maternal immunization and suggest that the COVID-19 vaccine be administered to pregnant women.

Collier et al. analyzed the immunogenicity of the mRNA vaccine in 22 pregnant women and 6 non-pregnant unvaccinated women with SARS-COV-2 infection. The receipt of the vaccine was immunogenic in pregnant women, and vaccine-elicited antibodies were transported to infant cord, blood and breast milk. In a related cohort study, Gray et al. found that COVID-19 messenger RNA vaccination in pregnancy and lactation generate robust humoral immunity similar to that observed in non-pregnant women. Vaccination allows the immune system of expectant mothers to be trained to recognize the spike protein of the SARS-COV-2 infection. Also, the side effects profile of pregnant women who receive the COVID-19 vaccine is not significantly different from the non-pregnant population. With mRNA vaccines, comparable humoral immunogenic responses are developed in both pregnant, lactating and non-pregnant populations. Data available indicate that
pregnant/breastfeeding women can generate a satisfactory immune response after COVID-19 vaccination. In a study that took serum samples of pregnant, non-pregnant 21 days after second vaccine dose and 26 days for lactating mothers after receiving mRNA-1272 and BNT162b vaccines respectively. 

Sufficient antibody titre against COVID-19 and the new variant is generated with pregnant/lactating women. 

T-cells responses were presented in both pregnant and non-pregnant women to the variant of concern suggesting cellular immune response is strong. 

In addition to these immunogenicities, Shimabukuro TT et al. reported preliminary findings of mRNA covid-19 vaccine safety in pregnant persons from three U.S vaccine safety monitoring systems: the “v-safe after vaccination health checker”, the V-safe pregnancy registry and the vaccine adverse events reporting system(VAERS). The study included data from these three sources from December 12, 2020, to February 28, 2021, and participants were aged 16–54 years. Among 2211 pregnancy-related adverse events reported to the VAERS, 46/221 were spontaneous abortions. For the V-safe pregnancy registry, 827 participants had a completed pregnancy, 115 recorded losses and 712(86.1%) pregnancy-related adverse events reported to the VAERS, 46/221 were spontaneous abortions. For the V-safe pregnancy registry, 827 participants had a completed pregnancy, 115 recorded losses and 712(86.1%) were live births. The calculated proportion of adverse outcomes were similar to incidences in the pre-pandemic period. Early data from these sources did not find any safety concerns for pregnant women and their babies. These preliminary findings did not show any signal or caution among pregnant women who received the mRNA COVID-19 vaccine. Except for intrapartum fever or temperature measuring above 38 reported by less than 1% of the participants on day 1 after the first dose and by 8% of the second dose, there were no intrapartum complications. Still in the U. S, a prospective cohort study conducted among adults who are pregnant, lactating or planning pregnancy by 8% of the second dose, there were no intrapartum complications. 

In a study which aimed to determine the maternal, neonatal and obstetric outcomes of 424 pregnant women who received a messenger RNA COVID-19 vaccine (Pfizer BioNtech) while pregnant found that cord blood from mothers had high anti-S IgG level because of maternal immunization. Thus, the effectiveness of the vaccine triggered the production of the antibodies capable of protecting the newborn from the infection. Their work also looked at antibodies to the nucleocapsid protein (anti-NlG) which were not seen suggesting the vaccine trigger antibodies to spike protein but not the prior infection. The significant vertical transfer of antibodies came from maternal vaccination rather than natural infection. Robust and comparable IgG titers are stronger in vaccinated pregnant women than the unvaccinated ones who got COVID-19. 

Patients with conditions such as diabetes, obesity, and preeclampsia still stand the chance to benefit from immunization against SARS-COV-2. The likelihood of poor maternal and neonatal outcome which increases with SARS-COV-2 infection become preventable with vaccination. It plays a vital role in the prevention of COVID-19 morbidity in pregnant patients. These are direct and compelling evidence of maternal benefits of COVID-19 vaccination in pregnancy, irrespective that clinical trials did not verify the safety of the vaccine. 

1.4. Infant protection associated with COVID-19 immunization

Neonates can acquire SARS-COV-2 in-utero from mothers with COVID-19 because of elevated IgM antibodies to SARS-COV-2 detected in neonates. One in 4 of all babies born to women with COVID-19 need admission to the neonatal unit or specialist care. Although the effect of SARS-COV2 on infants and neonates appear to be small or not well known. The infection has led to a significant risk of preterm births, fetal distress, respiratory distress, thrombocytopenia, and severe neonatal/perinatal morbidity index. This burden warrants the recommendation of antenatal immunization to protect both the mother and the infants. 

An immunogenicity study conducted by New York University Lancorne Health showed high levels of antibodies passed to babies. Antibodies crossing the placenta is a good thing and good safety data. The study which aimed to determine the maternal, neonatal and obstetric outcomes of 424 pregnant women who received a messenger RNA COVID-19 vaccine (Pfizer BioNtech) while pregnant found that cord blood from mothers had high anti-S IgG level because of maternal immunization. Thus, the effectiveness of the vaccine triggered the production of the antibodies capable of protecting the newborn from the infection. Their work also looked at antibodies to the nucleocapsid protein (anti-NlG) which were not seen suggesting the vaccine trigger antibodies to spike protein but not the prior infection. The significant vertical transfer of antibodies came from maternal vaccination rather than natural infection. Robust and comparable IgG titers are stronger in vaccinated pregnant women than the unvaccinated ones who got COVID-19. 

Antibodies also make their way to provide passive immunization via the milk of a lactating mother. The IgG antibodies are specific to vaccine response while IgA which comes from breastmilk following natural infection and recovery from COVID-19 and is present in all vaccine types. In women already breastfeeding, the robust antibodies (IgG and IgA) are generated 6 weeks following vaccination with the Pfizer-BioNTech. These generated antibodies may protect the baby in the first several months of life when the child is most vulnerable. The breastmilk also contains a large amount of IgA and IgG against SARS-COV-2 after the second dose of the COVID-19 vaccine. Amid the beneficial antibodies, studies are suggesting that there is an optimal trimester for the mother to get the jabs for maximum benefits. COVID-19 shots earlier in pregnancy are suggested to be better for the baby. The sooner pregnant women can get the vaccine the more likely the transfer of high level of protective antibodies.

A study that analyzed the blood and umbilical cord of 27 expectant women who received Pfizer Moderna vaccines pointed that a longer period between vaccination and delivery guarantees effective transfer of COVID-19 antibodies (immunoglobulin G) to newborns. Antibodies (IgG) were not seen in the blood sample of women who took the jabs less than 3 weeks before delivery. With factors associated with the efficiency of transfer, second dose vaccination significantly increased infant IgG levels. Infant antibody levels were also equal to maternal levels. There is no increased risk during pregnancy in the form of birth complications to the mother or the fetus among those who received the vaccine. In one study, the rate of spontaneous abortion and preterm birth recorded 6.5% and 5.9% respectively which were within or below the figures of the pre-pandemic period or national average. In a similar event reported in the UK, the number of miscarriages and stillbirths
registered in the summary of yellow for the COVID-19 vaccine was low to moderate. Pregnant women are more likely to get severely ill with COVID-19, and their newborns have a higher risk of being born prematurely. The vaccine protects pregnant women, and newborns also benefit from COVID-19 vaccinated mothers. Several studies have proved these benefits of the vaccine on both the mother and the baby. These findings support the vaccination as the best way to protect pregnant women and their babies against the known risk of SARS-CoV-2. With the increasing severity of COVID-19 in pregnancy amid the delta variant surge, pregnant women should be prioritized for COVID-19 vaccination while those planning conception need not delay taking the vaccines.

Conflict of interest
No conflict of interest to disclose.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.gynoec.2022.07.003.

References
1. Liu H, Wang LL, Zhao SJ, et al. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J Reprod Immunol. 2020;139:103122. https://doi.org/10.1016/j.jri.2020.103122.
2. Pregnant and Recently Pregnant People. Centers for Disease Control and Prevention. CDC. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/meet-extra-precautions/pregnant-people.html. [Last accessed on August 16, 2021].
3. Saadaoui M, Kumar M, Al Khodor S. COVID-19 Infection during pregnancy: risk of vertical transmission, fetal, and neonatal outcomes. J Periodontol. 2021;11(6):483. https://doi.org/10.3992/jpm11060483.
4. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Am Intern Med. 2020;172(9):577-582. https://doi.org/10.7326/M20-0504.
5. Sherer ML, Lei J, Creisher P, et al. Dysregulated immunity in SARS-CoV-2 infected pregnant women. Preprint. medRxiv. 2020;2021.11.13.20231737. https://doi.org/10.1101/2020.11.13.20231737.
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
7. Ashokka B, Loh MH, Tan CH, et al. Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergency cesarean delivery, differential diagnosis in the acute illness parturient, care of the newborn, and protection of the healthcare personnel. Am J Obstet Gynecol. 2020;223(1):66–74. https://doi.org/10.1016/j.ajog.2020.04.005, el.
8. Bouchghob H, Vigezziu S. De pregnant women have protective immunity against COVID-19? BLOG. 2020;127(10):1298–1299. https://doi.org/10.1111/1471-0528.16342.
9. Crovetto F, Grépi F, Llibre E, et al. Seroprevalence and presentation of SARS-CoV-2 in pregnancy. [published online...]. https://doi.org/10.1158/2326-9143.LNCR.2020;396(10250):530-531. https://doi.org/10.3174/0-406736(20) 31714-1.
10. Mullins E, Hushak ML, Banerjee J, et al. Pregnancy and neonatal outcomes of COVID-19: coro...nent of common outcomes from PAN-COVID and AAP-SOPFM registries.

2. Conclusion
This review shows that COVID-19 vaccines in pregnancy are safe, effective and beneficial. Pregnant individuals are more likely to get severely ill with COVID-19, and their newborns have a higher risk of being born prematurely. The vaccine protects pregnant women, and newborns also benefit from COVID-19 vaccinated mothers. Several studies have proved these benefits of the vaccine on both the mother and the baby. These findings support the vaccination as the best way to protect pregnant women and their babies against the known risk of SARS-CoV-2. With the increasing severity of COVID-19 in pregnancy amid the delta variant surge, pregnant women should be prioritized for COVID-19 vaccination while those planning conception need not delay taking the vaccines.
Fact Sheet for Vaccine Recipients & Caregivers Restricted Use in Emergency Situation for Covid-19 Covaxin SARS-CoV-2 Vaccine by Bharat Biotech. 2021. Available from: https://www.bharatbiotech.com/images/covaxin-covaxin-fact-sheet.pdf [Last accessed on July 16, 2022].

Moderna vaccines safe for pregnant women, lactating moms: Dr VK Paul. India Today. Available from: https://www.indiatoday.in/health/vaccine-recommendations-for-the-global-population. [Last accessed on July 16, 2022].

Vaccination Considerations for People Pregnant or Breastfeeding
Fact Sheet for Vaccine Recipients

50. Kachikis A, Englund JA, Singleton M, et al. Short-term reactions among pregnant and lactating women vaccinated against COVID-19. Vaccine. 2021;39(44):6535–6538. https://doi.org/10.1016/j.vaccine.2021.09.043.

51. Lampety E, Post-vaccination COVID-19 deaths: a review of available evidence and recommendations for the global population. Clin Exp Vaccine Res. 2021;10(3):264–275. https://doi.org/10.7774/cevr.2021.10.3.264.

52. Goldshtein I, Nevo D, Steinberg DM, et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. JAMA. 2021;326(8):728–735. https://doi.org/10.1001/jama.2021.11355.

53. Benefits Of Opening COVID-19 Vaccination for Pregnant Women Outweigh Theoretical Risks, Here's Why-India News. Firstpost. 2021. Available from: https://www.firstpost.com/india/benefits-of-opening-covid-19-vaccination-for-pregnant-women-outweigh-theoretical-risks-heres-why-9763141.html. [Last accessed on June 29, 2021].

54. Chavan M, Qureshi H, Kamati S, et al. COVID-19 vaccination in pregnancy: the benefits outweigh the risks. J Obstet Gynaecol Can. 2021;43(7):814–816. https://doi.org/10.1016/j.jogc.2021.03.010.

55. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51–60. https://doi.org/10.21037/tp.2020.02.06.

56. Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 3 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020;174(7):722–725. https://doi.org/10.1001/jamapediatrics.2020.0878.

57. Increasing Understanding of the Impact of COVID-19 for Pregnant Women and Their Babies. WHO; 2020. Available from: https://www.who.int/news/item/01-09-2020-increasing-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies. [Last accessed on September 4, 2021].

58. Healy CM. COVID-19 in pregnant women and their newborn infants. JAMA Pediatr. 2021;175(8):781–782. https://doi.org/10.1001/jamapediatrics.2021.1046.

59. Trostle ME, Limaye MA, Avutshka V, et al. COVID-19 vaccination in pregnancy: early experience from a single institution. Am J Obstet Gynecol MFM. 2021;3(6), 100464. https://doi.org/10.1016/j.jamfm.2021.100464.

60. Grell DS, Antibodies in breast milk remain for 10 months after COVID Infection – Study. The GuardianM. 2021. Available from: https://www.theguardian.com/lifeandstyle/2021/sep/27/antibodies-in-breast-milk-remain-for-10-months-after-covid-infection-study [Last accessed on July 16, 2022].

61. Yang X, Fox A, DeCarlo C, et al. Comparative profiles of SARS-CoV-2 spike-specific human milk antibodies elicited by mRNA- and adenovirus-based COVID-19 vaccines [published online ahead of print, 2022 Jun 8]. 10.1089/bfm.2022.0019 Breastfed Med. 2022. https://doi.org/10.1089/bfm.2022.0019.

62. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA. 2021;325(19):2013–2014. https://doi.org/10.1001/jama.2021.5782.

63. Newborns benefit from COVID-19 vaccinated mothers. Precision Vaccinations. Available from: https://www.precisionvaccinations.com/newborns-benefit-covid-19-vaccinated-mothers ; 2021. [Last accessed on November 11, 2021].

64. COVID Shot Earlier in Pregnancy Better for Baby: Study. US news & world report. U.S.News. Available from: www.unews.com/news/health/news/articles/2021-04-06/covid-shot-earlier-in-pregnancy-better-for-baby-study; 2021. [Last accessed on November 11, 2021].

65. Mithal LB, Otero S, Shanes ED, et al. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol. 2021;225(2):192–202. https://doi.org/10.1016/j.ajog.2021.03.035.

66. Trostle ME, Aguero-Rosenfeld ME, Roman AS, et al. High antibody levels in cord blood from pregnant women vaccinated against COVID-19. Am J Obstet Gynecol. 2021;326(8):728–735. https://doi.org/10.1016/j.ajog.2021.09.008.

67. Adhikari EE, SoRelle JA, McIntire DD, et al. Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge. Am J Obstet Gynecol. 2022;226(1):149–151. https://doi.org/10.1016/j.ajog.2021.09.008.